This project aims to evaluate the growth of anti-SARS-CoV2 antibodies in subjects who are vaccinated with various types of vaccines and how long these antibodies last over time. Both subjects who have had the infection and subjects who have never contracted Covid-19 are enrolled...
Patients with COVID-19 show a state of hypercoagulability (a strong activation of blood clotting) as shown by elevated levels of certain plasma proteins such as fibrinogen and d-dimer as well as a parallel increase in inflammation markers ( e.g. C reactive protein). In these...
The use of plasma from convalescent subjects, who survived the disease, as been used for other previous viral epidemics, such as for example Ebola, MERS-CoV (Middle East respiratory syndrome coronavirus, MERS-CoV), H1N1pdm09 (pandemic 2009 influenza A H1N1) , may have a...
Rationale: Management of anticoagulant therapy is a common problem in patients with thrombocytopenia secondary to cancer or antitumoral therapies. Anticoagulant therapy may be prescribed for various other conditions. These include venous thromboembolism (TEV), atrial...
Rationale: Venous thromboembolism (VTE), the term comprising deep venous thrombosis and pulmonary embolism, is a frequent complication of cancer, and is the second cause of death among these patients. Even when they have no overt thrombosis, cancer patients present a series...